Key result
Prognostic biomarkers and imaging remain vital for monitoring CAD progression and optimizing treatment plans.
Why the study?
A lack of cost-effective strategies for monitoring CAD prognosis creates a need to identify key biomarkers and imaging markers among over 1,000 candidates to assess disease severity, progression, and treatment efficacy.
Utilizing key prognostic biomarkers and imaging techniques can improve patient care, optimize treatment plans, and reduce healthcare costs associated with CAD management.
Answers are grounded in this paper and cite their sources.
Supports biomarker-guided CAD monitoring; leaves open prospective validation of optimal markers before routine adoption.
INTRODUCTION: Coronary Artery Disease (CAD) is a prevalent condition characterized by the presence of atherosclerotic plaques in the coronary arteries of the heart. The global burden of CAD has increased significantly over the years, resulting in millions of deaths annually and making it the leading health-care expenditure and cause of mortality in developed countries. The lack of cost-effective strategies for monitoring the prognosis of CAD warrants a pressing need for accurate and efficient markers to assess disease severity and progression for both reducing health-care costs and improving patient outcomes. AREA COVERED: To effectively monitor CAD, prognostic biomarkers and imaging techniques play a vital role in risk-stratified patients during acute treatment and over time. However, with over 1,000 potential markers of interest, it is crucial to identify the key markers with substantial utility in monitoring CAD progression and evaluating therapeutic interventions. This review focuses on identifying and highlighting the most relevant markers for monitoring CAD prognosis and disease severity. We searched for relevant literature using PubMed and Google Scholar. EXPERT OPINION: By utilizing the markers discussed, health-care providers can improve patient care, optimize treatment plans, and ultimately reduce health-care costs associated with CAD management.
No takes yet. Share an insight, caveat, or question.
Yazdani et al. (2023) conducted a review in Coronary Artery Disease (CAD). Biomarkers and imaging techniques was evaluated. Prognostic biomarkers and imaging techniques play a vital role in monitoring coronary artery disease progression and evaluating therapeutic interventions to optimize treatment plans.
Synapse has enriched 10 related papers. Consider them for comparative context: